Pacira Biosciences, Stock Working Capital

PCRX Stock

USD 25.48 0.38 1.51%

Pacira BioSciences, fundamentals help investors to digest information that contributes to Pacira BioSciences,'s financial success or failures. It also enables traders to predict the movement of Pacira Stock. The fundamental analysis module provides a way to measure Pacira BioSciences,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pacira BioSciences, stock.

	Last Reported	Projected for Next Year
Net Working Capital	474.5 M	402.2 M
Change In Working Capital	-41.2 M	-39.1 M

Net Working Capital is likely to drop to about 402.2 M in 2025. Change In Working Capital is likely to rise to about (39.1 M) in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pacira BioSciences, Company Working Capital Analysis

Pacira BioSciences,'s Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Pacira BioSciences, Working Capital

412.61 M

Most of Pacira BioSciences,'s fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pacira BioSciences, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pacira Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Pacira BioSciences, is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Working Capital. Since Pacira BioSciences,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira BioSciences,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira BioSciences,'s interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.46	0.95	0.43	0.63	0.97	0.97	0.32	0.97	0.84	0.34	0.95	0.64	0.97	-0.08	0.97	0.83	0.88	0.04	0.41	0.87	0.58	0.84
Total Stockholder Equity	0.97		0.49	0.91	0.49	0.65	0.93	0.99	0.34	0.88	0.74	0.16	0.92	0.63	0.98	-0.02	0.99	0.79	0.86	-0.04	0.21	0.91	0.7	0.91
Current Deferred Revenue	0.46	0.49		0.52	-0.06	0.51	0.48	0.43	0.69	0.41	0.52	-0.17	0.28	0.42	0.37	0.49	0.51	0.67	0.56	0.44	0.1	0.41	0.48	0.35
Net Debt	0.95	0.91	0.52		0.39	0.64	0.97	0.91	0.42	0.93	0.8	0.25	0.89	0.61	0.91	-0.03	0.93	0.85	0.86	0.23	0.34	0.88	0.51	0.79
Retained Earnings	0.43	0.49	-0.06	0.39		0.18	0.39	0.48	-0.39	0.34	0.03	-0.06	0.59	-0.21	0.47	-0.51	0.43	0.0	0.13	-0.3	-0.16	0.62	0.44	0.64
Accounts Payable	0.63	0.65	0.51	0.64	0.18		0.69	0.65	0.45	0.57	0.63	-0.16	0.57	0.42	0.63	0.21	0.68	0.77	0.77	0.12	0.03	0.64	0.56	0.58
Long Term Debt	0.97	0.93	0.48	0.97	0.39	0.69		0.94	0.32	0.95	0.81	0.23	0.95	0.62	0.95	-0.12	0.96	0.85	0.87	0.05	0.34	0.85	0.55	0.8
Net Receivables	0.97	0.99	0.43	0.91	0.48	0.65	0.94		0.24	0.89	0.72	0.17	0.96	0.62	0.99	-0.13	0.99	0.77	0.85	-0.13	0.23	0.89	0.65	0.9
Short Term Investments	0.32	0.34	0.69	0.42	-0.39	0.45	0.32	0.24		0.29	0.56	0.0	0.04	0.54	0.22	0.87	0.33	0.65	0.56	0.71	0.13	0.24	0.31	0.13
Total Liab	0.97	0.88	0.41	0.93	0.34	0.57	0.95	0.89	0.29		0.89	0.5	0.91	0.61	0.91	-0.12	0.89	0.81	0.85	0.11	0.57	0.79	0.44	0.73
Total Current Assets	0.84	0.74	0.52	0.8	0.03	0.63	0.81	0.72	0.56	0.89		0.54	0.69	0.74	0.74	0.22	0.75	0.88	0.91	0.28	0.63	0.67	0.47	0.56
Short Term Debt	0.34	0.16	-0.17	0.25	-0.06	-0.16	0.23	0.17	0.0	0.5	0.54		0.27	0.25	0.23	-0.1	0.14	0.15	0.27	0.07	0.86	0.11	-0.13	0.04
Intangible Assets	0.95	0.92	0.28	0.89	0.59	0.57	0.95	0.96	0.04	0.91	0.69	0.27		0.51	0.97	-0.35	0.93	0.68	0.76	-0.19	0.29	0.87	0.55	0.86
Common Stock	0.64	0.63	0.42	0.61	-0.21	0.42	0.62	0.62	0.54	0.61	0.74	0.25	0.51		0.63	0.24	0.64	0.81	0.83	0.15	0.29	0.58	0.44	0.51
Property Plant Equipment	0.97	0.98	0.37	0.91	0.47	0.63	0.95	0.99	0.22	0.91	0.74	0.23	0.97	0.63		-0.15	0.98	0.77	0.85	-0.14	0.27	0.88	0.63	0.88
Net Tangible Assets	-0.08	-0.02	0.49	-0.03	-0.51	0.21	-0.12	-0.13	0.87	-0.12	0.22	-0.1	-0.35	0.24	-0.15		-0.06	0.26	0.2	0.59	-0.02	-0.11	0.18	-0.18
Good Will	0.97	0.99	0.51	0.93	0.43	0.68	0.96	0.99	0.33	0.89	0.75	0.14	0.93	0.64	0.98	-0.06		0.83	0.88	-0.02	0.25	0.89	0.62	0.88
Long Term Debt Total	0.83	0.79	0.67	0.85	0.0	0.77	0.85	0.77	0.65	0.81	0.88	0.15	0.68	0.81	0.77	0.26	0.83		0.94	0.32	0.31	0.72	0.55	0.64
Capital Surpluse	0.88	0.86	0.56	0.86	0.13	0.77	0.87	0.85	0.56	0.85	0.91	0.27	0.76	0.83	0.85	0.2	0.88	0.94		0.18	0.38	0.83	0.59	0.73
Long Term Investments	0.04	-0.04	0.44	0.23	-0.3	0.12	0.05	-0.13	0.71	0.11	0.28	0.07	-0.19	0.15	-0.14	0.59	-0.02	0.32	0.18		0.2	0.02	-0.2	-0.18
Short Long Term Debt	0.41	0.21	0.1	0.34	-0.16	0.03	0.34	0.23	0.13	0.57	0.63	0.86	0.29	0.29	0.27	-0.02	0.25	0.31	0.38	0.2		0.11	-0.2	0.05
Net Invested Capital	0.87	0.91	0.41	0.88	0.62	0.64	0.85	0.89	0.24	0.79	0.67	0.11	0.87	0.58	0.88	-0.11	0.89	0.72	0.83	0.02	0.11		0.7	0.91
Net Working Capital	0.58	0.7	0.48	0.51	0.44	0.56	0.55	0.65	0.31	0.44	0.47	-0.13	0.55	0.44	0.63	0.18	0.62	0.55	0.59	-0.2	-0.2	0.7		0.76
Capital Stock	0.84	0.91	0.35	0.79	0.64	0.58	0.8	0.9	0.13	0.73	0.56	0.04	0.86	0.51	0.88	-0.18	0.88	0.64	0.73	-0.18	0.05	0.91	0.76

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Pacira BioSciences,

Working Capital Over Time

Pacira Capital Surpluse

Capital Surpluse

685.18 Million

At this time, Pacira BioSciences,'s Capital Surpluse is fairly stable compared to the past year.

Based on the company's disclosures, Pacira BioSciences, has a Working Capital of 412.61 M. This is 3.06% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 72.09% higher than that of the company.

Pacira Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences,'s direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences, could also be used in its relative valuation, which is a method of valuing Pacira BioSciences, by comparing valuation metrics of similar companies.

Pacira BioSciences, is currently under evaluation in working capital category among its peers.

Pacira BioSciences, ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pacira BioSciences,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pacira BioSciences,'s managers, analysts, and investors.

Environmental

Governance

Social

Pacira Fundamentals

	Return On Equity	-0.11
	Return On Asset	0.0417
	Profit Margin	(0.13) %
	Operating Margin	0.13 %
	Current Valuation	1.36 B
	Shares Outstanding	46.17 M
	Shares Owned By Insiders	3.21 %
	Shares Owned By Institutions	96.79 %
	Number Of Shares Shorted	5.14 M
	Price To Earning	14.34 X
	Price To Book	1.55 X
	Price To Sales	1.67 X
	Revenue	674.98 M
	Gross Profit	439.58 M
	EBITDA	157.58 M
	Net Income	41.95 M
	Cash And Equivalents	316.39 M
	Cash Per Share	6.90 X
	Total Debt	586.04 M
	Debt To Equity	1.10 %
	Current Ratio	3.95 X
	Book Value Per Share	16.24 X
	Cash Flow From Operations	154.65 M
	Short Ratio	5.95 X
	Earnings Per Share	(1.98) X
	Price To Earnings To Growth	(3.83) X
	Target Price	28.57
	Number Of Employees	711
	Beta	0.8
	Market Capitalization	1.16 B
	Total Asset	1.57 B
	Retained Earnings	(106.8 M)
	Working Capital	412.61 M
	Current Asset	252.58 M
	Current Liabilities	149.79 M
	Net Asset	1.57 B

About Pacira BioSciences, Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC